This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Stealth BioTherapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
14.4%
Earnings growth rate
62.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 19.7% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Stealth BioTherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 0 | -53 | 20 | 27 |
| 30 Sep 21 | 0 | -51 | 20 | 25 |
| 30 Jun 21 | 0 | -56 | 20 | 24 |
| 31 Mar 21 | 0 | -50 | 19 | 26 |
| 31 Dec 20 | 0 | -57 | 19 | 29 |
| 30 Sep 20 | 21 | -35 | 20 | 35 |
| 30 Jun 20 | 21 | -41 | 22 | 38 |
| 31 Mar 20 | 21 | -44 | 23 | 40 |
| 31 Dec 19 | 21 | -72 | 22 | 45 |
| 30 Sep 19 | 0 | -102 | 26 | 45 |
| 30 Jun 19 | 0 | -108 | 25 | 51 |
| 31 Mar 19 | 0 | -120 | 23 | 54 |
| 31 Dec 18 | 0 | -97 | 22 | 53 |
| 30 Sep 18 | 0 | -92 | 16 | 59 |
| 31 Dec 17 | 0 | -83 | 17 | 63 |
Quality Earnings: S1BA is currently unprofitable.
Growing Profit Margin: S1BA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: S1BA is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare S1BA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: S1BA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15%).
Return on Equity
High ROE: S1BA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.